[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-367815-en":59,"doc-seo-367815-105":98},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":41,"preview_page_count":19,"preview_urls":80},367815,2336478487870,"Jasmine","https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","NUTM2A-AS1 as a potential key regulator in cancer - unraveling its ceRNA networks and impact on tumor biology","NUTM2A-AS1 is an emerging long noncoding RNA (lncRNA) implicated in cancer through ceRNA network mechanisms that sequester microRNAs and reshape gene expression to influence oncogenic pathways. This review synthesizes experimental, clinical, and bioinformatics evidence on NUTM2A-AS1 involvement across multiple cancers, highlighting expression patterns, mechanistic findings, and clinical correlations. Reported examples include gastric cancer effects on TET1/HIF-1A and PD-L1, hepatocellular carcinoma activation of Wnt/β-catenin signaling, and neuroblastoma-driven chemoresistance and metastasis via B7-H3 stabilization, alongside similar ceRNA axes in colorectal, glioma, lung adenocarcinoma, and prostate cancer. The lncRNA is also included in prognostic signatures for renal cell carcinoma, supporting its potential as a biomarker and therapeutic target, with future work emphasizing in vivo studies and clinical trials using CRISPR and single-cell RNA sequencing.","Pourianazar etal. European Journal  \nEuropean Journal of Medical Research (2025) 30:840  \n[https://doi.org/10.1186/s40001-025-03019-y](https://doi.org/10.1186/s40001-025-03019-y of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-025-03019-y of Medical Research)  \n REVIEW Open Access  \nNUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networksand impact on tumor biology  \nNegarTaghavi Pourianazar1, Safa Radmehr2*, Zahra Ourang3, Kaveh Jaseb2 and Alireza Asadi4  \nAbstract  \nNUTM2A-AS1 is an emerging long noncoding RNA (lncRNA) that has garnered significant attention due to its multifaceted roles in cancer biology. As a member of the ceRNA network, NUTM2A-AS1 modulates gene expression by sequestering microRNAs, thereby influencing key oncogenic pathways. This review aims to provide a comprehensive overview of the current understanding of NUTM2A-AS1 in the development, progression, and metastasis of various cancers, including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma. A systematic evaluation of experimental, clinical, and bioinformatics studies was conducted, with an emphasis on studies reporting expression patterns, mechanistic insights, and clinical correlations. Key findings reveal that in gastric cancer, NUTM2A-AS1 functions as a ceRNA for miR-376a, leading to upregulation ofTET1 and HIF-1A and subsequent increase in PD-L1 expression, while also modulating matrine resistance via the miR-613/ROS/VEGFA axis. In hepatocellular carcinoma, it sponges miR-186-5p, thereby derepressing KLF7 and activating the Wnt/β catenin pathway. Neuroblastoma studies demonstrate that NUTM2A-AS1 enhances chemoresistance and metastasis through stabilization of B7-H3, mediated by NR1D1 . In colorectal cancer, its transcriptional activation by H3K27 acetylation enables it to sequester miR-126-5p and upregulate FAM3C. Similar ceRNA-driven mechanisms involving miR-376a-3p/YAP1 in glioma, miR-590-5p/METTL3 in lung adenocarcinoma, and miR-376a-3p/PRMT5 in prostate cancer further underscore its oncogenic potential. In addition, NUTM2A-AS1 is incorporated into prognostic lncRNA signatures for renal cell carcinoma. The clinical implications of these findings are significant, as NUTM2A-AS1 holds promise as a biomarker for cancer diagnosis and prognosis and as a target for novel therapeutic strategies. Future research should prioritize in vivo studies and clinical trials, leveraging emerging technologies such as CRISPR and single-cell RNA sequencing, to fully elucidate the therapeutic potential of targeting NUTM2A-AS1 in personalized cancer treatment.  \nKeywords Neoplasms, ceRNA, Long noncoding RNAs, NUTM2A-AS1, Biomarker  \n*Correspondence:  \nSafa Radmehr[safa.radmehr1398@gmail.com](safa.radmehr1398@gmail.com)  \n1 Medical Laboratory Techniques, Istanbul Aydin University, Istanbul, Turkey  \n2 Thalassemia & Hemoglobinopathy Research Center/ Health Research Institute/Ahvaz,, Ahvaz, Iran  \n3 Arak University of Medical Sciences, Arak, Iran  \n4 Dentistry School, Shiraz University of Medical Sciences, Shiraz, Iran  \nBackground  \nCancer has been recognized as the second-leading cause of death globally, with its burden manifested through millions of fatalities and an enormous impact on public health, society, and economies [1]. In 2020, cancer was implicated in approximately 5.5 million deaths among men and 4.4 million among women [2]. The devastating toll of the disease has been observed not only in direct mortality but also in the broader societal repercussions,  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if ","cbCainBmfxlaOxwW","https://ap.wps.com/l/cbCainBmfxlaOxwW","pdf",1417157,12,"English","en",105,"# Abstract\n# Background\n## Cancer burden worldwide\n## Noncoding RNAs and oncogenesis\n# Keywords","[{\"question\":\"What role does NUTM2A-AS1 play in cancer biology?\",\"answer\":\"NUTM2A-AS1 functions as an emerging long noncoding RNA that participates in ceRNA networks by sequestering microRNAs and thereby modulating gene expression and oncogenic pathways.\"},{\"question\":\"Which cancers are discussed with specific NUTM2A-AS1 mechanisms?\",\"answer\":\"The review covers gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma, describing distinct ceRNA axes and downstream effects.\"},{\"question\":\"How could NUTM2A-AS1 be used clinically?\",\"answer\":\"Findings indicate that NUTM2A-AS1 may serve as a biomarker for cancer diagnosis and prognosis and as a target for novel therapeutic strategies.\"}]","NUTM2A-AS1 as a potential key regulator in cancer - unraveling its ceRNA networks and impact on tumor biology | PDF",1790172815,[81,85,89,94],{"page_no":8,"url":82,"width":83,"height":84},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fedc4356387e6b53cecd9d831add73a0.webp",983,1305,{"page_no":14,"url":86,"width":87,"height":88},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4c211e7ae33e84a04b1f4d873f8e831.webp",982,1304,{"page_no":90,"url":91,"width":92,"height":93},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f48eb6f3be70e8bf50561620779f801.webp",981,1303,{"page_no":19,"url":95,"width":96,"height":97},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49834fdf15742767497b559f4a2b3be1.webp",980,1301,{"code":4,"msg":99,"data":100},"ok",{"site_id":75,"language":74,"slug":101,"title":65,"keywords":102,"description":66,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"nutm2a-as1-as-a-potential-key-regulator-in-cancer-unraveling-its-cerna-networks-and-impact-on-tumor-biology","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":9,"@type":111,"position":14},"https://docshare.wps.com/document/",{"item":115,"name":40,"@type":111,"position":90},"https://docshare.wps.com/document/research-report/",{"item":117,"name":65,"@type":111,"position":19},"https://docshare.wps.com/document/nutm2a-as1-as-a-potential-key-regulator-in-cancer-unraveling-its-cerna-networks-and-impact-on-tumor-biology/367815/",{"url":117,"name":65,"@type":119,"image":120,"author":125,"headline":65,"publisher":127,"fileFormat":130,"inLanguage":74,"description":66,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/nutm2a-as1-as-a-potential-key-regulator-in-cancer-unraveling-its-cerna-networks-and-impact-on-tumor-biology/367815.png","ImageObject",300,407,{"name":63,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":135,"interactionType":136,"userInteractionCount":52},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"What role does NUTM2A-AS1 play in cancer biology?","Question",{"text":145,"@type":146},"NUTM2A-AS1 functions as an emerging long noncoding RNA that participates in ceRNA networks by sequestering microRNAs and thereby modulating gene expression and oncogenic pathways.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"Which cancers are discussed with specific NUTM2A-AS1 mechanisms?",{"text":150,"@type":146},"The review covers gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma, describing distinct ceRNA axes and downstream effects.",{"name":152,"@type":143,"acceptedAnswer":153},"How could NUTM2A-AS1 be used clinically?",{"text":154,"@type":146},"Findings indicate that NUTM2A-AS1 may serve as a biomarker for cancer diagnosis and prognosis and as a target for novel therapeutic strategies.","https://schema.org",{"og:url":117,"og:type":157,"og:title":65,"og:site_name":128,"og:description":66},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":61,"site_id":75},1790229314]